Sign up
Pharma Capital

Shield's Feraccru likely to command 'high market share and branded pricing'

Capital Network analyst Emma Ulker assesses recent progress made at Shield Therapeutics PLC (LON:STX) with its lead asset Feraccru.

The drug's approved and marketed in Europe, with a US approval decision pending for July 27.

Feraccru is an oral product absorbed in the gut. It's also an alternative for those unable to tolerate or unresponsive to first-line salt-based oral iron products.

 

View full STX profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.